checkAd

     157  0 Kommentare NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility - Seite 2

    For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.

    For more information, please contact:

    Dr. Lior Shaltiel
    Chief Executive Officer and Director
    Phone: +972-52-4803034
    Email: info@nurexone.com

    Thesis Capital Inc.
    Investment Relation - Canada
    Phone: +1 905-347-5569
    Email: IR@nurexone.com

    Dr. Eva Reuter
    Investment Relation - Germany
    Phone: +49-69-1532-5857
    Email: e.reuter@dr-reuter.eu

    FORWARD-LOOKING STATEMENTS

    This press release contains certain forward-looking statements, including statements about the Company's future plans and intellectual property, the scientific and development and commercial activities to be carried out by the company, the efficient loading of exosomes, future potential manufacturing, clinical, licensing and marketing activities the treatment of certain conditions, trading the Company’s common shares on the OTCQB, and DTC eligibility. Wherever possible, words such as "may", "will", "should", "could", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict" or "potential" or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof. Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. Certain assumptions include the ability of the Company to commercialize its intellectual property internally and through licensing and that the Company has the appropriate team in order to realize commercialization. Risks and uncertainties include, but are not limited to, risks related to the Company's early stage of development, lack of revenues to date, government regulation, market acceptance for its products, rapid technological change, dependence on key personnel, protection of the Company's intellectual property and dependence on the Company's strategic partners. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

    Seite 2 von 3


    Diskutieren Sie über die enthaltenen Werte

    Aktuelle Themen


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility - Seite 2 TORONTO and HAIFA, Israel, April 25, 2024 (GLOBE NEWSWIRE) - NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company is pleased to announce that its common shares are now quoted for …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer